RNA-seq

If the results are validated, investigators believe the method could help diagnose patients without the need for a needle biopsy and with fewer false positives.

Fulgent and its China-based joint venture  are  working on a clinical NGS-based  test that  it says will have better  sensitivity than RT-PCR-based kits.

The company believes results from a new study help demonstrate the clinical value of its targeted RNA-seq method, an add-on to its DNA hereditary cancer tests.

The company's approach involves using both fluorescence in situ hybridization and next-generation sequencing to provide clinicians with information.

Formerly called OncoCell MDx, the Royal Oak, Michigan-based firm aims to complete a validation study for the prostate cancer risk assay within the next two months.

Researchers in the US and the United Arab Emirates found that RNA-seq in B-lymphoblastoid cell lines can help identify pathogenic variants that DNA testing missed.

While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.